The Biosimilar Red Tape Elimination Act, H.R. 5526, which is cosponsored by U.S. Rep. Greg Landsman (D-OH), would automatically deem “biosimilar” drugs as interchangeable with their name-brand counterparts upon approval by the Food and Drug Administration (FDA). “Our healthcare system is unfortunately marked by skyrocketing costs, especially when it comes to prescription drugs. “Health care needs real reform, and we can start by making prescription drugs more affordable for everyone,” said Rep. Landsman. The measure has gained support from the Biosimilars Forum, the Biosimilars Council, and the Campaign for Sustainable Rx Pricing.